Virtual Library

Start Your Search

Qin Yin Yin



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-111 - Clinical Features and Prognosis of Eighty-Five Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma (ID 12363)

      16:45 - 18:00  |  Presenting Author(s): Qin Yin Yin

      • Abstract
      • Slides

      Background

      Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of lung cancer that is less reported and not well understood around the world.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A retrospective analysis of clinical features for 85 patients was conducted to determine the prognostic factors in terms of age, gender, radiographic features, serum tumor markers, TNM stages, pathological features, treatment and prognosis.

      4c3880bb027f159e801041b1021e88e8 Result

      PLELC preferentially affects the young (< 60 years old: 71.8%) nonsmokers (72.9%), without significant difference in gender. The median follow-up time was 15 months (1-37 months) for the whole group and most patients were in the early stage with opportunity of operation (50.6%). For the advanced stage group, patients mainly received chemotherapies and radiotherapies, the 0.5-year and 1.5-year PFS rates were 61% and 29%, respectively. The TNM stage (P=0.014) and performance status (PS) (P=0.040) were associated with PFS significantly in the univariate analysis, while TNM stage was an independent prognostic factor in multivariate analysis (P=0.026). In the subtype analysis, patients in the advanced stage receiving Gemcitabine plus platinum (GP group) or Paclitaxel plus platinum (TP group) had better PFS than Pemetrexed plus platinum (PP group) (P=0.005).

      8eea62084ca7e541d918e823422bd82e Conclusion

      PLELC had a better prognosis compared with other types of non-small cell lung cancer (NSCLC) and was sensitive to radiotherapy and chemotherapy. The current results recommended that the GP and TP should be used as first-line treatment of PLELC. The TNM stage and PS were predictive in prognosis of PLELC patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.